Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEP++ for prevention of leprosy transmission
NL-OMON23060Recruiting
- Sponsor
- NLR Bio
- Start
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of rifampicin and clarithromycin in leprosy (HD) (2 arms), sponsored by NLR Bio. Primary endpoints: Rate ratio of leprosy case detection among close contacts and District-level decline in case detection rate. Started Aug 2018; status: recruiting.
02
Drugs
rifampicinclarithromycin
03
Conditions
leprosy (HD)
Beyond the preview
Go deeper on NL-OMON23060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON23060.